• Jan. 29, 2014, 8:29 AM
    • Fluidigm (FLDM) agrees to acquire DVS Sciences for $207.5M in cash and stock in a deal it says will enable it to offer a comprehensive portfolio of advanced technologies serving the growing single-cell genomics and proteomics markets.
    • FLDM says DVS is best known for its multi-parameter single-cell protein analysis systems, including the the CyTOF2 Mass Cytometer, which analyzes antibody/metal complexes using atomic mass spectrometry.
    Jan. 29, 2014, 8:29 AM